Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 10/20 | 0.40 |
| ▸ | CNR1 | P21554 | 6/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10080080 | 0.91 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL3070301 | 0.89 | MAPT (0.43) | SIGMAR1TMEM97ALDH1A1HPGDCNR2 | |
| SCHEMBL177191 | 0.87 | CNR2 (0.44) | CNR2CNR1 | |
| SCHEMBL3076484 | 0.87 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL3076479 | 0.87 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL176466 | 0.83 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL3090276 | 0.81 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL10080076 | 0.81 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL10080077 | 0.81 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL3093466 | 0.80 | CNR2 (0.48) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119621-B2 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | disclosed |
| US-8119621-B2 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | disclosed |
| US-20100279991-A1 | TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100279991-A1 | TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7790718-B2 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790718-B2 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20070191362-A1 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191362-A1 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007035945-A1 | TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191362-A1 | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators | CNR1, CNR2, GPR18 | SIGMAR1 576/4885TMEM97 510/4885KDM4E 1758/4885 |
| US-20100279991-A1 | TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS | CNR1, CNR2, GPR18 | SIGMAR1 576/4885TMEM97 510/4885KDM4E 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.